Bionure initiates a Phase I clinical trial of its lead compound BN201 in the UK

by Gemma Escarré,

Bionure, member of CataloniaBio & HealthTech that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces the initiation of a Phase I clinical trial of its lead compound BN201 in the United Kingdom.

BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases.

The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new Chief Medical Officer (CMO). Dr Smith is a Senior Advisor/Consultant with the Bill and Melinda Gates Foundation.

Alta Life Sciences is leading a Series A round of 4 million euros to finance the clinical development of the BN201 for AON and NMO, that affects 130,000 patients a year only in United States and Europe which give a potential market of about €1,000 million/year.

More information

Photo: Mar Massó, Managing Director of Bionure - © Bionure

Comments


To comment, please login or create an account